TheraLin®

Developed by scientists at George Mason University, TheraLin® fixative allows for standardization of biopsy collection, fixation, and the pathologist’s workflow, providing equivalent immunohistochemistry and cytological assessment to standard formalin fixation, including H&E staining, and does not interfere with antigen retrieval for a variety of immunostaining procedures. It requires no special handling, can be used at ambient temperatures, and collected biopsies can be stored prior to processing at refrigeration temperatures (4ºC). Samples can be processed using standard methodologies for ethanol based embedding in paraffin, and blocks can be stored for extended periods for future analysis.

TheraLin ® is a registered trademark of Theranostics Health Inc.
US Patent 8460859

Products

Id Title
210050 TheraLin® Universal Tissue Fixative - 50mL Info
210100 TheraLin® Universal Tissue Fixative - 100mL Info
210250 TheraLin® Universal Tissue Fixative - 250mL Info
Request a quote for the selected products

Enabling Molecular Pathology

TheraLin® supports standard histopathology and immunocytochemistry performed by pathologists and researchers, and allows for the isolation of nucleic acids, proteins and importantly, phosphoproteins which are critical for understanding the activity of cellular signaling pathways.

  • Formalin-free, does not contain carcinogens
  • Preserves tissues for paraffin embedding
  • Does not require special handling, can be used at ambient temperatures
  • Biopsies may be stored in TheraLin at room temperature or refrigerated (2-8°C) prior to processing
  • Allows for standardization of biopsy collection, fixation, and tissue processing
  • Preserves morphology of cells for cytopathological classification using H&E
  • Calcified tissues (bone) do not require additional decalcification steps
  • Allow for the routine immunohistochemical analysis of known biomarkers
  • Preserves intact DNA, RNA, total proteins and modified proteins
  • Compatible with standard protocols for nucleic acid isolation and does not interfere with PCR or array-based analytical systems

About Theralin

TheraLin® fixative was developed under a series of NIH grants awarded under the NCI IMAT program to Dr. Lance Liotta and Dr.Virginia Espina. Dr. Liotta is a co-founder of Theranostics Health and current Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University. The fixative not only preserves the morphology of tissues and cells, allowing pathologists to conduct standard immuno-histochemistry and histopathology procedures, but also preserves the integrity of proteins, and more importantly, modified proteins, such as phosphoproteins, which are an indication of a protein’s activity. TheraLin®, which contains no formalin, supports multiple, downstream processes, ranging from routine histopathological analysis to more specific biomarker applications.

TheraLin® fixative allows for standardization of biopsy collection, fixation, and the pathologist’s workflow, providing equivalent immunohistochemistry and cytological assessment to standard formalin fixation, including H&E staining, and does not interfere with antigen retrieval for a variety of immunostaining procedures. It requires no special handling, can be used at ambient temperatures, and collected biopsies can be stored at refrigeration temperatures (4C) prior to processing.   Samples can be processed using standard methodologies for ethanol based embedding in paraffin, and blocks can be stored for extended periods for future analysis.

TheraLin ® is a registered trademark of Theranostics Health Inc.

TheraLin® Universal Tissue Fixative embodies technology developed by scientists at George Mason University, Center for Applied Proteomics and Molecular Medicine with Funding from the National Cancer Institute : Innovative Molecular Analysis Technologies (NCI IMAT R21CA125698 & R33CA157403) and licensed from Theranostics Health, Inc. US Patent 8460859.